Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close
Published on 09/25/2026 at 19:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences closed at USD 149.69 on Nasdaq on September 25, 2026, down USD 1.68 or 1.11 percent. The shares underperformed the Nasdaq Composite by 1.81 percentage points, with the index up 0.7 percent at 12:12 p.m. ET. Gilead's next scheduled event is a USD 0.82 per share dividend payment on September 29, 2026.
The session on September 25, 2026 in figures
Gilead Sciences, Inc. (ISIN US3755581036) opened at USD 150.88 after a previous close of USD 151.37. The stock reached a session high of USD 152.975 and a low of USD 149.69. The shares finished at the low, leaving a daily range of USD 3.285. Nasdaq data showed volume of 4,793,456 shares against average volume of 6,642,350 shares.
The closing price stood USD 7.60 below the 52-week high of USD 157.29, a distance of 4.83 percent. The stock remained USD 41.23 above the 52-week low of USD 108.46. FundSpec listed Gilead at USD 149.69 with a one-month gain of 0.62 percent on its September 25, 2026 update. The session therefore ended below the previous close despite the broader technology-heavy index trading higher intraday.
Analyst estimate raised as rate pressure persists
Erste Group Bank raised its FY2027 earnings-per-share estimate for Gilead to USD 9.88 from USD 9.86 in a note issued on September 18, 2026, as MarketBeat reported. The same report listed a consensus rating of Moderate Buy and an average price target of USD 158.78. The report also recorded a USD 0.82 quarterly dividend scheduled for payment on September 29, 2026.
Higher Treasury yields remained a market pressure point on September 25, 2026. As CNBC reported, the 10-year Treasury yield reached 5.230 percent intraday, its highest level since June 15, 2007. The report also cited strong economic data, elevated energy prices and hawkish Federal Reserve commentary as market influences. Reuters had reported on September 24, 2026, that the 10-year yield rose to 5.196 percent and that futures priced a 71 percent chance of a rate increase in October.
Nasdaq, biotechnology peers and the late session
Nasdaq Composite performance stood at a 0.7 percent gain at 12:12 p.m. ET on September 25, 2026, while the Dow was up 0.9 percent. FundSpec listed Amgen at USD 406.04, down 0.01 percent, and Vertex Pharmaceuticals at USD 522.38, up 1.17 percent. Regeneron Pharmaceuticals stood at USD 796.02, down 0.72 percent, according to FundSpec. Gilead's 1.11 percent decline therefore lagged Vertex by 2.28 percentage points and Amgen by 1.10 points.
Dividend payment scheduled for September 29, 2026
Gilead's next dated corporate event is the payment of its USD 0.82 quarterly dividend on September 29, 2026. The payment follows the September 15, 2026 ex-dividend date listed by MarketBeat. The next five trading days also include the scheduled payment, which matters for holders focused on the distribution record.
